



Our ref: FOI 1502

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Information regarding how many non-small cell lung cancer (NSCLC) patients were treated in the last 3 months has now been considered and the information requested is enclosed.

Enc FOI 1502

Question:

Part 1:

Dear Southern Health and Social Care Trust,

I am analysing the treatment of lung cancer and would greatly appreciate if you could answer the following question:

In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

- Afatinib
- Alectinib
- Amivantamab
- Atezolizumab monotherapy
- Atezolizumab with chemotherapy
- Brigatinib
- Ceritinib
- Crizotinib
- Dacomitinib
- Dabrafenib with Trametinib
- Durvalumab
- Erlotinib
- Gefitinib
- Lorlatinib
- Mobocertinib
- Nintedanib with Docetaxel
- Nivolumab
- Osimertinib

Part 2:

- Pembrolizumab monotherapy
- Pembrolizumab with chemotherapy
- Pemetrexed with Carboplatin/Cisplatin
- Pralsetinib
- Selpercatinib
- Sotorasib
- Tepotinib
- Vinorelbine with Carboplatin/Cisplatin
- Any other active systemic anti-cancer therapy (SACT)
- Palliative care only

Answer:-

Part 1:

- Afatinib - 0
- Alectinib – <5
- Amivantamab - 0

foi.team@southerntrust.hscni.net

- Atezolizumab monotherapy - 0
- Atezolizumab with chemotherapy - 0
- Brigatinib-0
- Ceritinib -0
- Crizotinib-0
- Dacomitinib-0
- Dabrafenib with Trametinib-0
- Durvalumab -<5
- Erlotinib - <5
- Gefitinib -0
- Lorlatinib-0
- Mobocertinib-0
- Nintedanib with Docetaxel-0
- Nivolumab-0
- Osimertinib-8pt

Part 2:

- Pembrolizumab monotherapy-15pts
- Pembrolizumab with chemotherapy – <5
- Pemetrexed with Carboplatin/Cisplatin -13pts
- Pralsetinib – 0pts
- Selpercatinib– 0pts
- Sotorasib– 0pts
- Tepotinib– 0pts
- Vinorelbine with Carboplatin/Cisplatin– 0pts
- Any other active systemic anti-cancer therapy (SACT) Gem/carbo- <5, Pac/carbo <5, oral vinorelbine <5.
- Palliative care only – unable to confirm.

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.